rhBSSL + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Replacement Therapy in Preterm Infants
Conditions
Replacement Therapy in Preterm Infants
Trial Timeline
Mar 1, 2008 → Feb 1, 2010
NCT ID
NCT00659243About rhBSSL + Placebo
rhBSSL + Placebo is a phase 2 stage product being developed by Swedish Orphan Biovitrum for Replacement Therapy in Preterm Infants. The current trial status is completed. This product is registered under clinical trial identifier NCT00659243. Target conditions include Replacement Therapy in Preterm Infants.
What happened to similar drugs?
3 of 11 similar drugs in Replacement Therapy in Preterm Infants were approved
Approved (3) Terminated (2) Active (6)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00658905 | Phase 2 | Completed |
| NCT00659243 | Phase 2 | Completed |
Competing Products
20 competing products in Replacement Therapy in Preterm Infants